News archive

Here, Center Director Hans-Gustaf Ljunggren present some personal recollections and reflections of research in the field of NK cells and work conducted in his laboratory over three decades, leading up towards the current utilization of NK cells in the context of human cancer immunotherapy.

What do you know about ATMPs? Equip yourself for the future – learn the basics of Advanced Therapy Medicinal Products (ATMP). Join in and take the Swedish healthcare into the future!

Hans-Gustaf Ljunggren, Director, will participate in the digital event - Cell & Gene Therapy 2021, May 18-19. Hans-Gustaf will present one of the Competence Center’s projects - Autologous NK Cells as Consolidation Therapy in Multiple Myeloma.

The symposium is a joint mini symposium between the NextGenNK partners Karolinska Institutet and Sanofi.

XNK Therapeutics AB (“XNK”) has entered into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab)

Karl-Johan Malmberg, co-director of NextGenNK will present his research and the Competence Center at the digital event - Allogeneic Cell Therapies Summit 2021, May 17-19. The meeting is focused on the clinical and commercial development of engineered allogeneic cell therapies and innovating off-the shelf therapies to benefit patients in need.

The Directors of NextGenNK will present their research and the Competence Center at the digital event - Innate Killer Summit 2021, March 23-25. The meeting will focus on NK cell-based immunotherapies and their clinical translation.

NextGenNK sets out to deepen its interactions with health care units. Activities, when applicable, will be integrated with the Vinnova funded CAMP, that focuses specifically on GMP-bioprocess development, production and distribution logistics.

Avectas and Vycellix Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies. NextGenNK catalyzed interaction among its industrial partners to advance NK cell-based immunotherapies